Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Aripiprazole Articles

18 new blockbusters by 2008, with $24 billion sales forecast

1 July 2002

B-MS has better news on pipeline with antipsychotic data and HIV drug filing

3 June 2002

Bristol-Myers Squibb's earnings sink as generic competition takes hold

6 May 2002

Bristol-Myers Squibb issues profit warning for 2002

15 April 2002

Bristol-Myers Squibb slumps as Vanlev data disappoints

25 March 2002

Files aripiprazole in EU

7 January 2002

B-MS predicts EPS decline in 2002

7 January 2002

Files aripiprazole in EU

17 December 2001

B-MS predicts EPS decline in 2002

17 December 2001

Bristol-Myers Squibb highlights five key products at R&D day

15 November 2001

B-MS and Otsuka submit aripiprazole

8 November 2001

Pfizer launches assault on Eli Lilly in antipsychotic drug sector

9 May 2001

B-MS to file NDA for Abilitat in 4th quarter

27 April 2001

B-MS focuses on intense growth and reveals product pipeline

2 October 2000

B-MS reveals Ph III aripiprazole data

17 May 2000

US pharmaceutical majors show strong sales growth for third quarter

20 October 1999

B-MS, Otsuka link up on new antipsychotic

22 September 1999

Showing 101-117 of 117 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • AstraZeneca plans to move three cancer drug candidates into Ph III
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS